Tharimmune raises $1.74mln through direct offering.

Tharimmune has priced a $1.74 million direct public offering of common stock and warrants. The offering consists of 414,331 shares, 559,910 pre-funded warrants, and 974,241 warrants to acquire common stock at an exercise price of $1.66 per share. Net proceeds will be used for working capital and general corporate purposes. The stock price dropped 1.8% on Wednesday during after-market hours trading.

Tharimmune, Inc. (NASDAQ: THAR), a clinical-stage biotechnology company focused on pioneering therapies in immunology and inflammation, has priced a $1.74 million registered direct public offering (RD Offering) of common stock and warrants. The offering includes 414,331 shares of common stock, 559,910 pre-funded warrants, and 974,241 warrants to acquire common stock at an exercise price of $1.66 per share. The units, comprising one share of common stock or pre-funded warrant and a common warrant, are priced at $1.786 per unit [1].

Proceeds from the offering, expected to be approximately $1.74 million before deducting placement agent fees and estimated offering expenses, will be used for working capital and general corporate purposes [1]. President Street Global, LLC is serving as the exclusive placement agent for the offering, which is expected to close around July 25, 2025, subject to customary closing conditions [1].

The RD Offering is part of a shelf registration statement on Form S-3, which was previously filed with the U.S. Securities and Exchange Commission (SEC) and became effective on March 24, 2023 [1]. A preliminary prospectus supplement and accompanying prospectus have been filed with the SEC, and a final prospectus supplement will be filed upon completion of the offering [1].

Tharimmune's stock experienced a 1.8% drop during after-market hours trading on Wednesday, July 2, 2025 [2].

References:
[1] https://www.biospace.com/press-releases/tharimmune-announces-pricing-of-1-74-million-registered-direct-public-offering-of-common-stock-and-warrants
[2] https://www.stocktitan.net/news/THAR/tharimmune-announces-pricing-of-1-74-million-registered-direct-bz882m3tfrqt.html